Gardasil® 9 protects against nine types of human papillomavirus (HPV) infection. HPV types 6 and 11 cause anogenital warts and HPV types 16, 18, 31, 33, 45, 52, 58 can cause persistent infection leading to mouth, throat, cervical, vaginal, vulvar, penile and anal cancers. The Ministry of Health information pamphlet Immunise against HPV (code HE2012) is available from www.healthed.govt.nz. The pamphlet is also available electronically in Chinese Simplified, Chinese Traditional, Cook Islands Māori, Hindi, Māori, Sāmoan, and Tongan.
An HPV update presented by the NZ Society of Otolaryngology – Head & Neck Surgery and NZ HPV Project, supported by the Immunisation Advisory Centre.
Health professionals in primary and secondary care, and District Health Board and The University of Auckland staff are invited to attend an HPV update on Wednesday 23 March 2016 at The University of Auckland School of Medicine.
Speakers, Dr Bruce Haughey, Kimbrough Endowed Professor and Director of the Head and Neck Fellowship program in the Department of Otolaryngology at Washington University School of Medicine in St. Louis, USA and Dr Julian White, Otolaryngologist – Head & Neck Surgeon at Waikato Hospital, will discuss the changing epidemiology and pathology of HPV disease, treatment, primary and secondary disease prevention, and the role of the HPV vaccine.
Download your invitation to The Male Story - Emerging Epidemic of HPV Related Head and Neck Cancer. Please RSVP to Claire Hurst by Monday 21 March if you would like to attend the update, her contact details are available on the invitation.
Gardasil 9 is a new vaccine that protects against nine human papillomavirus (HPV) types, the same four types in Gardasil plus five additional types with cancer causing potential.
Protection against HPV types 31, 33, 45, 52, and 58 in Gardasil 9 can prevent 20 percent more cervical, vulvar, and vaginal cancers than the Gardasil vaccine. Both Gardasil 9 and Gardasil protect against the potential cancer causing HPV types 16 and 18 and against genital warts caused by HPV types 6 and 11. Oral and anal cancers in men and women as well as cervical, vulvar, and vaginal cancers in women have been linked to infection with HPV types 16 and 18.
Gardasil 9 is currently only approved for use in the U.S.
The Austalian National Immunisation Programme will include the human papillomavirus vaccine (Gardasil®) for 12 and 13 year old boys from 2013.
Boys in year 9 will also be eligible for the vaccine through a school-based catch-up programme. The vaccine covers two types of human papillomavirus (HPV) that cause genital warts and two types that can cause chronic HPV infection and increase the risk of penile, anal and oropharyngeal cancers in men.
Australia has recorded a decrease pre-cancerous cervical changes in women since the introduction of the vaccine and the Pharmaceutical Benefits Advisory Committee recommended the immunisation programme be extended to include the vaccine for boys following a review of its cost effectiveness.
New Zealand is seeing the same decreasing trend in the number of new genital warts cases since the Gardasil vaccine was introduced as Australia experienced after introducing the vaccine in July 2007.
The Institute of Environmental Science & Research Limited (ESR) monitors the voluntary provision of sexually transmitted infection data and prepares an annual report examining infection trends over time.
The Sexually transmitted infections in New Zealand 2011 Surveillance Report identified decreasing numbers of new genital warts cases between 2008 and 2011. The decreased numbers were most notable in 2010 and 2011 and in females aged 15-19 years. This decrease corresponds with commencement of the HPV immunisation programme (Gardasil) in June 2008. The report is available in full from the ESR Public Health Surveillance website.
Research comparing the number of new cases of genital warts in females who have received the Gardasil vaccine compared with females who have not would provide additional evidence to support this trend.
If the New Zealand continues to follow Australia’s trend for decreasing cases of genital warts, young heterosexual men will also have a significant decrease in new cases through reduced exposure to the infections in young women in the following years.
Figure: Genital warts case numbers in sexual health clinics by District Health Board, 2006-2011. ESR Surveillance Report, Sexually transmitted infections in New Zealand 2011, page 55.
Gardasil® protects against four types of human papillomavirus (HPV) infection. HPV types 6 and 11 cause anogenital warts and HPV types 16 and 18 can cause persistent infection leading to mouth, throat, cervical, vaginal, vulvar, penile and anal cancers.